Content about Chemistry

April 23, 2014

Bayer HealthCare on Tuesday announced that the Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation for Bayer's investigational Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) for the treatment of non-cystic fibrosis bronchiectasis.

WHIPPANY, N.J. — Bayer HealthCare on Tuesday announced that the Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation for Bayer's investigational Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) for the treatment of non-cystic fibrosis bronchiectasis. Patients with NCFB suffer from frequent severe acute pulmonary bacterial exacerbations, which lead to further inflammation, airway and lung parenchyma damage.

April 23, 2014

Nutrition 21 on Tuesday announced that it has entered into a multi-year license agreement with Church & Dwight for the use of chromium picolinate in Church & Dwight’s dietary supplement products.

PURCHASE, N.Y. — Nutrition 21 on Tuesday announced that it has entered into a multi-year license agreement with Church & Dwight for the use of chromium picolinate in Church & Dwight’s dietary supplement products.  

April 21, 2014

GlaxoSmithKline and Genmab A/S announced last week that the Food and Drug Administration has approved a supplemental biologic license application for the use of Arzerra (ofatumumab) in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia for whom fludarabine-based therapy is considered inappropriate.

LONDON — GlaxoSmithKline and Genmab A/S announced last week that the Food and Drug Administration has approved a supplemental biologic license application for the use of Arzerra (ofatumumab) in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukemia for whom fludarabine-based therapy is considered inappropriate.

April 21, 2014

McNeil Consumer Healthcare recently introduced a new form to the Zyrtec portfolio of allergy-relief products — an oral, dissolvable tablet.

FORT WASHINGTON, Pa. — McNeil Consumer Healthcare recently introduced a new form to the Zyrtec portfolio of allergy-relief products — an oral, dissolvable tablet. Delivering the same effective 24-hour relief, Zyrtec Dissolve Tabs contains 10 mg of citrus-flavored cetirizine that melts in the mouth.

April 21, 2014

MD Science Lab on Monday launched a new personal lubricant called Swiss Navy Sensitive Skin.

POMPANO BEACH, Fla. — MD Science Lab on Monday launched a new personal lubricant called Swiss Navy Sensitive Skin. The new, all-natural lubricant caters to men and woman with sensitive skin.

April 18, 2014

Actavis on Friday announced that it has entered into agreements with Akorn and Hi-Tech Pharmacal to purchase four currently marketed products and one product under development for cash consideration.

DUBLIN — Actavis on Friday announced that it has entered into agreements with Akorn and Hi-Tech Pharmacal to purchase four currently marketed products and one product under development for cash consideration. The closing of the purchase agreements are contingent upon the consummation of Akorn's acquisition of Hi-Tech. Financial terms of the agreements were not disclosed.

April 17, 2014

Mylan announced the launch of Xulane (norelgestromin/ethinyl estradiol transdermal system 150/35-mcg per day), the generic version of Ortho Evra (norelgestromin/ethinyl estradiol transdermal system 150/35-mcg per day) from Janssen Pharmaceuticals.

PITTSBURGH — Mylan announced the launch of Xulane (norelgestromin/ethinyl estradiol transdermal system 150/35-mcg per day), the generic version of Ortho Evra (norelgestromin/ethinyl estradiol transdermal system 150/35-mcg per day) from Janssen Pharmaceuticals. The drug is used to prevent pregnancy in women who want to use a transdermal patch as a contraception method.

April 16, 2014

Dr. Reddy's Labs announced the launch of eszopiclone tablets (C-IV) in 1-mg, 2-mg and 3-mg form. The drug is the generic version of Lunesta (eszopiclone) tablets.

HYDERABAD, India — Dr. Reddy's Labs announced the launch of eszopiclone tablets (C-IV) in 1-mg, 2-mg and 3-mg form. The drug is the generic version of Lunesta (eszopiclone) tablets.

The Lunesta tablets brand and generic combined had sales in the United States of approximately $887 million for the most recent twelve months ending in January 2014, according to IMS Health. Dr. Reddy's eszopiclone tablets 1-mg is available in bottle counts of 30; 2-mg and 3-mg tablets are available in bottle counts of 100.

April 15, 2014

Actavis on Tuesday announced that it has entered into an agreement with Mylan and Famy Care to settle all outstanding patent litigation related to Mylan's generic version of Generess FE (norethindrone, ethinyl estradiol and ferrous fumarate chewable tablets).

DUBLIN — Actavis on Tuesday announced that it has entered into an agreement with Mylan and Famy Care to settle all outstanding patent litigation related to Mylan's generic version of Generess FE (norethindrone, ethinyl estradiol and ferrous fumarate chewable tablets).

Under the terms of the agreement, Actavis will grant Mylan a license to market its generic version of Generess FE under its pending abbreviated new drug application beginning on April 1, 2015.

April 15, 2014

Unilever’s Caress brand has named Adriana Castro, designer, style trendsetter and founder of El Diario de la Moda, as its new Caress Fabulistas to help celebrate the launch of the new Caress Fresh Body Wash collection.

ENGLEWOOD CLIFFS, N.J. — Unilever’s Caress brand has named Adriana Castro, designer, style trendsetter and founder of El Diario de la Moda, as its new Caress Fabulistas to help celebrate the launch of the new Caress Fresh Body Wash collection.

April 15, 2014

The Food and Drug Administration on Friday announced a meeting of the Nonprescription Drugs Advisory Committee on May 2 to discuss the potential switch of Merck's Singulair Allergy tablets.

SILVER SPRING, Md. — The Food and Drug Administration on Friday announced a meeting of the Nonprescription Drugs Advisory Committee on May 2 to discuss the potential switch of Merck's Singulair Allergy tablets. 

The proposed OTC use is "temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: Nasal congestion, runny nose, itchy, watery eyes, sneezing, itching of the nose.” The applicant proposes to label the product for OTC use in adults 18 years and older. 

April 15, 2014

Greenstone, a generic pharmaceutical subsidiary of Pfizer, announced the introduction of amlodipine besylate/atorvastatin calcium tablets to its roster of products.

PEAPACK, N.J. — Greenstone, a generic pharmaceutical subsidiary of Pfizer, announced the introduction of amlodipine besylate/atorvastatin calcium tablets to its roster of products. The drug is the authorized generic versions of Caduet.

April 15, 2014

Mylan announced that it has launched eszopiclone tablets in 1 mg, 2 mg and 3 mg form.

PITTSBURGH — Mylan announced that it has launched eszopiclone tablets in 1 mg, 2 mg and 3 mg form. The drug — which is used for the treatment of insomnia — is the generic version of Lunesta from Sunovion Pharmaceuticals.

Mylan received final approval from the Food and Drug Administration for its abbreviated new drug application. Eszopiclone tablets had sales in the U.S. of approximately $851.8 million for the 12 months ending Dec 31, 2013, according to IMS Health.

 

April 15, 2014

Teva Pharmaceutical Industries announced the launch of a generic equivalent to Lunesta (eszopiclone tablets) in 1-,2- and 3-mg form in the United States.

JERUSALEM — Teva Pharmaceutical Industries announced the launch of a generic equivalent to Lunesta (eszopiclone tablets) in 1-,2- and 3-mg form in the United States. The drug is used to treat insomnia.

Lunesta tablets, which are marketed by Sunovion Pharmaceuticals, had annual sales of $852 million in the United States as of December 2013, according to IMS data.

 

April 11, 2014

Mylan on Friday confirmed that a federal district court has granted its request to enforce a settlement agreement between Endo Pharmaceuticals and Mylan settling patent litigation in connection with Mylan's filing of an abbreviated new drug application with the Food and Drug Administration for frovatriptan succinate tablets, 2.5 mg.

PITTSBURGH — Mylan on Friday confirmed that a federal district court has granted its request to enforce a settlement agreement between Endo Pharmaceuticals and Mylan settling patent litigation in connection with Mylan's filing of an abbreviated new drug application with the Food and Drug Administration for frovatriptan succinate tablets, 2.5 mg. This product is the generic version of Frova, which is used to treat acute migraine headaches in adults. 

April 11, 2014

The creator of Merlot Skin Care and First Crush has unveiled a new skin care collection that not only aims to hydrate, heal and protect skin but to also make a difference in the lives of veterans.

EL PASO, Texas — The creator of Merlot Skin Care and First Crush has unveiled a new skin care collection that not only aims to hydrate, heal and protect skin but to also make a difference in the lives of veterans. Enter Camo Cream.

With every purchase of Camo Cream, a portion of the sale goes toward Homes For Our Troops, a national nonprofit that works to build homes for post-9/11 injured veterans. Homes For Our Troops has built more than 160 homes nation wide, with plans to build dozens more.

April 10, 2014

Ambi, a beauty brand for women of color, is expanding its portfolio with the new Ambi Advanced 5% Micro-Benzoyl Peroxide Acne Spot Treatment and Ambi Even & Clear Makeup Removing Cleansing Cloths.

NEW YORK — Ambi, a beauty brand for women of color, is expanding its portfolio with the new Ambi Advanced 5% Micro-Benzoyl Peroxide Acne Spot Treatment and Ambi Even & Clear Makeup Removing Cleansing Cloths.

April 10, 2014

Lupin announced that it received final approval from the Food and Drug Administration for pioglitazone tablets USP in 15-mg, 30-mg and 45-mg strengths.

MUMBAI and BALTIMORE — Lupin announced that it received final approval from the Food and Drug Administration for pioglitazone tablets USP in 15-mg, 30-mg and 45-mg strengths. The product is the generic version of Actos tablets from Takeda Pharmaceuticals.

The drug is used an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes. Actos tablets had annual sales in the United States of approximately $236 million as of December 2013, according to IMS MAT data. 

 

April 9, 2014

GM Pharmaceuticals recently announced the addition of 8-oz. bottles to its line of liquid pain relief VanaPain.

ARLINGTON, Texas — GM Pharmaceuticals recently announced the addition of 8-oz. bottles to its line of liquid pain relief VanaPain. The new bulk products for the chronic pain sufferer begin shipping in July, and the suggested retail price ranges from $7.99 to $9.99. 

April 9, 2014

Procter & Gamble has declared a commitment to no deforestation in its palm oil supply chain by improving practices with all its suppliers, including small local farmers, to ensure protection of forests, the company announced on Tuesday.

CINCINNATI — Procter & Gamble has declared a commitment to no deforestation in its palm oil supply chain by improving practices with all its suppliers, including small local farmers, to ensure protection of forests, the company announced on Tuesday.

According to P&G, it uses very little actual palm oil in its products, but derivatives and by-products of palm oil are found in a variety of its beauty and household care products, such as detergents, shampoos, hand and body cleansers, bar soaps and color cosmetics.

April 8, 2014

Diplomat on Monday announced that it is one of a select group of specialty pharmacies contracted by Celgene to distribute Otezla (apremilast), a new medication for the treatment of psoriatic arthritis.

FLINT, Mich. — Diplomat on Monday announced that it is one of a select group of specialty pharmacies contracted by Celgene to distribute Otezla (apremilast), a new medication for the treatment of psoriatic arthritis. Otezla is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). 

Otezla was approved by the FDA on March 21, 2014, and is available in 10 mg, 20 mg and 30 mg tablets. 

April 8, 2014

Sunovion Pharmaceuticals on Monday announced that Aptiom (eslicarbazepine acetate), a once-daily antiepileptic drug, is now available across the United States.

MARLBOROUGH, Mass. — Sunovion Pharmaceuticals on Monday announced that Aptiom (eslicarbazepine acetate), a once-daily antiepileptic drug, is now available across the United States.

The drug, which received approval from the Food and Drug Administration on Nov. 8, 2013, is a prescription medicine used with other medicines to treat partial-onset seizures. The drug is available in four table strengths: 200 mg, 400 mg, 600 mg and 800 mg; it can be taken whole or crushed, with food or without.

April 7, 2014

Boehringer Ingelheim Pharmaceuticals announced that the Food and Drug Administration has approved Pradaxa (dabigatran etexilate mesylate), which is used to treat deep venous thrombosis and pulmonary embolism.

RIDGEFIELD, Conn. — Boehringer Ingelheim Pharmaceuticals announced that the Food and Drug Administration has approved Pradaxa (dabigatran etexilate mesylate). The drug is indicated for the treatment of deep venous thrombosis and pulmonary embolism in patients who have received a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated, the company said.

April 7, 2014

Mallinckrodt and Questcor Pharmaceuticals on Monday announced that they have entered into a definitive merger agreement under which Mallinckrodt will acquire Questcor in a transaction valued at approximately $5.6 billion.

DUBLIN — Mallinckrodt and Questcor Pharmaceuticals on Monday announced that they have entered into a definitive merger agreement under which Mallinckrodt will acquire Questcor in a transaction valued at approximately $5.6 billion. The transaction was unanimously approved by the boards of directors of both companies. Subject to customary closing conditions, the transaction currently is expected to be completed in the third calendar-quarter of 2014.

April 4, 2014

The National Association of Boards of Pharmacy recommended that pharmacies no longer dispense combination drugs containing more than 325 mg of acetaminophen per dosage unit in light of recent regulatory action.

MOUNT PROSPECT, Ill. — The National Association of Boards of Pharmacy on Wednesday recommended that pharmacies no longer dispense combination drugs containing more than 325 mg of acetaminophen per dosage unit in light of recent regulatory action.  

NABP also advises that pharmacists consult with prescribers to discuss alternative products with lower acetaminophen doses.